Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts

@inproceedings{Marquez2014EvaluationO8,
  title={Evaluation of 89Zr-pertuzumab in Breast
Cancer Xenografts},
  author={Bernadette V. Marquez and Oluwatayo F. Ikotun and Alexander Zheleznyak and B. D. Wright and Amrita Hari-Raj and Richard A. Pierce and Suzanne Elizabeth Lapi},
  booktitle={Molecular pharmaceutics},
  year={2014}
}
Pertuzumab is a monoclonal antibody that binds to HER2 and is used in combination with another HER2-specific monoclonal antibody, trastuzumab, for the treatment of HER2+ metastatic breast cancer. Pertuzumab binds to an HER2 binding site distinct from that of trastuzumab, and its affinity is enhanced when trastuzumab is present. We aim to exploit this enhanced affinity of pertuzumab for its HER2 binding epitope and adapt this antibody as a PET imaging agent by radiolabeling with (89)Zr to… CONTINUE READING